Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
JY Wu, SG Wu, CH Yang, YL Chang, YC Chang… - Lung cancer, 2011 - Elsevier
INTRODUCTION: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
[HTML][HTML] Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating …
WS Wu, YM Chen, CM Tsai… - Experimental and …, 2012 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective
treatment for advanced non-small cell lung cancer. The objective of the present study was to …
treatment for advanced non-small cell lung cancer. The objective of the present study was to …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
[HTML][HTML] Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
AS Wong, R Soong, SBK Seah, SW Lim… - Journal of Thoracic …, 2008 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
[HTML][HTML] Comparison of clinical outcomes following gefitinib and erlotinib treatment in non–small-cell lung cancer patients harboring an epidermal growth factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - Elsevier
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
[HTML][HTML] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib
Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …